Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

BackgroundHuangci Granule is a traditional Chinese medicine for treating metastatic colorectal cancer (mCRC).ObjectiveTo evaluate the efficacy and safety of Huangci Granule combination with chemotherapy and cetuximab (CET) or bevacizumab (BV) for treating mCRC.MethodsWe performed a randomized, contr...

Full description

Bibliographic Details
Main Authors:	Ningning Liu, Chaojun Wu, Ru Jia, Guoxiang Cai, Yan Wang, Lihong Zhou, Qing Ji, Hua Sui, Puhua Zeng, Haijuan Xiao, Huaimin Liu, Jiege Huo, Yuanyuan Feng, Wanli Deng, Qi Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-04-01
Series:	Frontiers in Pharmacology
Subjects:	traditional Chinese medicine metastatic colorectal cancer cetuximab (CET) or bevacizumab (BV) progression-free survival quality of life
Online Access:	https://www.frontiersin.org/article/10.3389/fphar.2020.00478/full

Similar Items

Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
by: Cheng, C.-L, et al.
Published: (2022)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
by: Yu‐Wen Zhou, et al.
Published: (2021-05-01)

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
by: Bobo Zheng, et al.
Published: (2019-03-01)

Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab
by: Joan Manel Gasent Blesa, et al.
Published: (2012-12-01)

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study
by: Chunlong Huang, et al.
Published: (2021-01-01)

Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer
by: CHENG Jianping, et al.
Published: (2020-07-01)

Cetuximab in first line treatment of metastatic colorectal cancer
by: Carlo Barone, et al.
Published: (2012-07-01)

Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report
by: Toyama Yoichi, et al.
Published: (2012-06-01)

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
by: Buchler T, et al.
Published: (2018-12-01)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
by: Alessandro Ottaiano, et al.
Published: (2018-05-01)

Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer
by: Ying-nan Yang, et al.
Published: (2018-10-01)

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer
by: Hanna Barmettler, et al.
Published: (2012-08-01)

Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis
by: Jiang W, et al.
Published: (2018-07-01)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
by: Andrea Uhlyarik, et al.
Published: (2020-03-01)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
by: Vivek Subbiah, et al.
Published: (2020-04-01)

Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol
by: Shang-Hung Chen, et al.
Published: (2019-06-01)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
by: Mengping Zhang, et al.
Published: (2020-06-01)

The efficacy of clobetasol, dexpanthenol, and fucidic acid in the treatment of cetuximab-induced skin toxicity
by: Didem Tastekin
Published: (2017-06-01)

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial
by: Bekaii-Saab, T., et al.
Published: (2022)

Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study
by: Hui-Ching Wang, et al.
Published: (2020-09-01)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with <i>RAS</i> Wild Type Metastatic Colorectal Cancer
by: Said A. Khelwatty, et al.
Published: (2021-02-01)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
by: Bai L, et al.
Published: (2019-12-01)

CLINICAL EXPERIENCE OF PROLONGED BEVACIZUMAB THERAPY IN METASTATIC COLORECTAL CANCER
by: I. S. Bulavina, et al.
Published: (2015-02-01)

Clinical case use bevacizumab for patient with metastatic ovarian cancer
by: M. R. Oganyan, et al.
Published: (2014-07-01)

Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study
by: Carmine Pinto, et al.
Published: (2016-11-01)

First-line molecular therapies in the treatment of metastatic colorectal cancer – a literature-based review of phases II and III trials
by: Vogel Arndt, et al.
Published: (2018-05-01)

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
by: Ulivi Paola, et al.
Published: (2012-05-01)

Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck
by: Jacques Bernier
Published: (2011-12-01)

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
by: Carin A. Uyl-de Groot, et al.
Published: (2018-07-01)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
by: Dalyong Kim, et al.
Published: (2017-11-01)

Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
by: Georgios Tsakonas, et al.
Published: (2020-10-01)

Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer
by: Xu R, et al.
Published: (2018-12-01)

BEVACIZUMAB COMBINED WITH IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN AS THE FIRST- LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA
by: Deyan Davidov
Published: (2014-12-01)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
by: Ocvirk Janja, et al.
Published: (2016-06-01)

TWO PROGRAMS OF CHEMOTHERAPY IN COMBINATION WITH BEVACIZUMAB IN THE TREATMENT OF DISSEMINATED COLORECTAL CANCER
by: O. V. Zharkova, et al.
Published: (2015-02-01)

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
by: Thomas Chevalier, et al.
Published: (2021-06-01)

Preliminary results of an observational program for estimating the duration of bevacizumab therapy in patients with metastatic colorectal cancer in daily clinical practice
by: I V Poddubnaya, et al.
Published: (2013-03-01)

Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis
by: Muhammad Khan, et al.
Published: (2021-02-01)

SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients
by: Zhu Mei, et al.
Published: (2018-04-01)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
by: Frifeldt Sanne K, et al.
Published: (2011-03-01)